Blinatumomab-话题@MedSci - 梅斯（MedSci）

#Blinatumomab#

4篇内容 | 1232人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2218758, encodeId=2a7e2218e5890, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a> <a href='/topic/show?id=f751352108' target=_blank style='color:#2F92EE;'>#Blinatumomab#</a> <a href='/topic/show?id=a649121941c' target=_blank style='color:#2F92EE;'>#MRD#</a>, objectTitle=NEJM | 探索新疗法：Blinatumomab联合化疗改善MRD阴性BCP-ALL患者总生存期, objectType=article, longId=837787, objectId=aa9083e787d1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240718/1721281386020_92910.jpg, objectUrl=/article/show_article.do?id=aa9083e787d1, replyNumber=0, likeNumber=79, createdTime=2024-08-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=aa9083e787d1, moduleTitle=NEJM | 探索新疗法：Blinatumomab联合化疗改善MRD阴性BCP-ALL患者总生存期, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=aa9083e787d1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1685380, encodeId=579016853803d, content=<a href='/topic/show?id=f751352108' target=_blank style='color:#2F92EE;'>#Blinatumomab#</a>, objectTitle=JAMA：Blinatumomab vs 化疗用于首次复发的B细胞急性淋巴细胞白血病儿童、青少年和年轻患者, objectType=article, longId=207857, objectId=663420e857ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=663420e857ae, replyNumber=0, likeNumber=74, createdTime=2021-08-17, rootId=0, userName=zengjiayao, userId=7bf328156681, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=663420e857ae, moduleTitle=JAMA：Blinatumomab vs 化疗用于首次复发的B细胞急性淋巴细胞白血病儿童、青少年和年轻患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=663420e857ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685381, encodeId=2800168538130, content=<a href='/topic/show?id=f751352108' target=_blank style='color:#2F92EE;'>#Blinatumomab#</a>, objectTitle=JAMA：Blinatumomab可提高首次复发的B细胞急性淋巴细胞白血病高危患儿无事件生存率, objectType=article, longId=207858, objectId=4adc20e8585b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4adc20e8585b, replyNumber=0, likeNumber=0, createdTime=2021-12-15, rootId=0, userName=zengjiayao, userId=7bf328156681, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4adc20e8585b, moduleTitle=JAMA：Blinatumomab可提高首次复发的B细胞急性淋巴细胞白血病高危患儿无事件生存率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4adc20e8585b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685379, encodeId=c08a16853e98b, content=<a href='/topic/show?id=f751352108' target=_blank style='color:#2F92EE;'>#Blinatumomab#</a>, objectTitle=The lancet oncology：白血病治疗的曙光！blinatumomab试验效果乐观, objectType=article, longId=45203, objectId=ca4545203c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca4545203c0, replyNumber=0, likeNumber=61, createdTime=2015-05-13, rootId=0, userName=zengjiayao, userId=7bf328156681, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca4545203c0, moduleTitle=The lancet oncology：白血病治疗的曙光！blinatumomab试验效果乐观, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ca4545203c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685378, encodeId=5fd716853e821, content=<a href='/topic/show?id=f751352108' target=_blank style='color:#2F92EE;'>#Blinatumomab#</a>, objectTitle=安进BiTE免疫疗法收获在望——提交全球BiTE疗法blinatumomab上市申请, objectType=article, longId=40707, objectId=85ed40e07b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85ed40e07b0, replyNumber=0, likeNumber=67, createdTime=2015-08-15, rootId=0, userName=zengjiayao, userId=7bf328156681, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85ed40e07b0, moduleTitle=安进BiTE免疫疗法收获在望——提交全球BiTE疗法blinatumomab上市申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=85ed40e07b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Blinatumomab

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#ALL# #Blinatumomab# #MRD#

NEJM | 探索新疗法：Blinatumomab联合化疗改善MRD阴性BCP-ALL患者总生存期

2024-08-06发表于上海

zengjiayao (审核中...)

前往app查看评论内容

#Blinatumomab#

JAMA：Blinatumomab vs 化疗用于首次复发的B细胞急性淋巴细胞白血病儿童、青少年和年轻患者

2021-08-17

zengjiayao (审核中...)

前往app查看评论内容

#Blinatumomab#

JAMA：Blinatumomab可提高首次复发的B细胞急性淋巴细胞白血病高危患儿无事件生存率

2021-12-15

zengjiayao (审核中...)

前往app查看评论内容

#Blinatumomab#

The lancet oncology：白血病治疗的曙光！blinatumomab试验效果乐观

2015-05-13

zengjiayao (审核中...)

前往app查看评论内容

#Blinatumomab#

安进BiTE免疫疗法收获在望——提交全球BiTE疗法blinatumomab上市申请

2015-08-15

科室
- - 订阅+
  - 更多科室
工具
服务